- Home
- AQB vs NDRA Comparison
AQB vs NDRA Comparison
Compare AQB & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AQB
- NDRA
- Stock Information
- Founded
- AQB 1991
- NDRA 2007
- Country
- AQB United States
- NDRA United States
- Employees
- AQB N/A
- NDRA N/A
- Industry
- AQB
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AQB
- NDRA Health Care
- Exchange
- AQB Nasdaq
- NDRA Nasdaq
- Market Cap
- AQB 3.0M
- NDRA 3.0M
- IPO Year
- AQB N/A
- NDRA 2017
- Fundamental
- Price
- AQB $0.75
- NDRA $4.89
- Analyst Decision
- AQB Hold
- NDRA Strong Buy
- Analyst Count
- AQB 2
- NDRA 1
- Target Price
- AQB N/A
- NDRA $14,000.00
- AVG Volume (30 Days)
- AQB 221.1K
- NDRA 20.1K
- Earning Date
- AQB 11-05-2024
- NDRA 03-27-2025
- Dividend Yield
- AQB N/A
- NDRA N/A
- EPS Growth
- AQB N/A
- NDRA N/A
- EPS
- AQB N/A
- NDRA N/A
- Revenue
- AQB $1,258,512.00
- NDRA N/A
- Revenue This Year
- AQB N/A
- NDRA N/A
- Revenue Next Year
- AQB $43.65
- NDRA N/A
- P/E Ratio
- AQB N/A
- NDRA N/A
- Revenue Growth
- AQB N/A
- NDRA N/A
- 52 Week Low
- AQB $0.47
- NDRA $4.01
- 52 Week High
- AQB $2.79
- NDRA $2,240.00
- Technical
- Relative Strength Index (RSI)
- AQB 50.10
- NDRA 40.73
- Support Level
- AQB $0.68
- NDRA $4.80
- Resistance Level
- AQB $0.98
- NDRA $5.65
- Average True Range (ATR)
- AQB 0.09
- NDRA 0.47
- MACD
- AQB -0.00
- NDRA -0.11
- Stochastic Oscillator
- AQB 33.93
- NDRA 12.00
About AQB AquaBounty Technologies Inc.
AquaBounty Technologies Inc is engaged in the field of land-based aquaculture and the use of technology to improve the productivity and sustainability. The company's objective is to ensure the availability of high-quality seafood to meet consumer demand while addressing critical production constraints in the popular farmed species.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI but at 1/50th the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.